We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
Read MoreHide Full Article
Key Takeaways
BSX's EP business is expected to grow nearly 15% over the LRP, driven by share gains and ICE entry.
BSX's WATCHMAN remains the top LAAC device, with growth tied to positive OPTION and CHAMPION trial results.
Boston Scientific's ICTx, its most global cardiovascular unit, targets 10% growth and aims to beat markets.
Boston Scientific’s (BSX - Free Report) Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace end-market growth rates and also be accretive to the company’s target of more than 10% average organic revenue growth. Electrophysiology (“EP”), one of the fastest growing businesses, is expected to grow roughly 15% over the LRP, driven by continued share gains and expansion into additional EP areas, such as the $1 billion Intracardiac Echocardiography space.
Meanwhile, Boston Scientific’s WATCHMAN remains the leading device in percutaneous LAAC globally. Management’s long-term view of WATCHMAN as a 20%+ growth engine is contingent upon positive outcomes from the OPTION trial, already published in the New England Journal of Medicine, and the upcoming CHAMPION trial readout in the first half of 2026.
The company’s CRM DX business — covering active implantables, pacemakers and others — is expected to grow about 4% over the LRP. Recent investments in the conduction system pacing, entry into the leadless market in modular therapies and the launch of a new platform midway through the plan are expected to support a return to at least market-level growth.
The Interventional Cardiology Therapies (ICTx) is the company’s most global Cardiovascular business, with strong development in the Emerging Markets, such as Asia, the Middle East, Africa, and Latin America, helping it sustain a double-digit growth rate. The company forecasts 10% growth for ICTx and intends to outperform the rate. The Peripheral Interventions, Interventional Oncology and Embolics businesses collectively represent $11 billion, growing around 7%, with the company aiming to grow above market as well.
Update From Boston Scientific’s Peers
Medtronic (MDT - Free Report) announced that its Diabetes business, soon to operate under the name MiniMed, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected to be completed through a series of capital markets transactions, preferably via an IPO and subsequent split-off. Additionally, Medtronic’s Hugo robotic-assisted surgery (RAS) system has secured FDA approval for use in urologic surgical procedures.
Johnson & Johnson (JNJ - Free Report) has completed the acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. With this acquisition, Johnson & Johnson adds HLD-0915, a clinical-stage therapy for prostate cancer, building on its nearly two decades of innovation in this disease area. In addition, the European Commission has approved the company’s TREMFYA (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor.
BSX Price Performance, Valuation and Estimates
In the past year, BSX shares have climbed 7.5% compared with the industry’s 1.7% rise.
Image Source: Zacks Investment Research
BSX shares are trading at a forward, five-year Price-to-Earnings (P/E) ratio of 27.81, above its median and the industry average.
Image Source: Zacks Investment Research
See how analysts are projecting Boston Scientific’s 2025 and 2026 earnings.
Image: Bigstock
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
Key Takeaways
Boston Scientific’s (BSX - Free Report) Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace end-market growth rates and also be accretive to the company’s target of more than 10% average organic revenue growth. Electrophysiology (“EP”), one of the fastest growing businesses, is expected to grow roughly 15% over the LRP, driven by continued share gains and expansion into additional EP areas, such as the $1 billion Intracardiac Echocardiography space.
Meanwhile, Boston Scientific’s WATCHMAN remains the leading device in percutaneous LAAC globally. Management’s long-term view of WATCHMAN as a 20%+ growth engine is contingent upon positive outcomes from the OPTION trial, already published in the New England Journal of Medicine, and the upcoming CHAMPION trial readout in the first half of 2026.
The company’s CRM DX business — covering active implantables, pacemakers and others — is expected to grow about 4% over the LRP. Recent investments in the conduction system pacing, entry into the leadless market in modular therapies and the launch of a new platform midway through the plan are expected to support a return to at least market-level growth.
The Interventional Cardiology Therapies (ICTx) is the company’s most global Cardiovascular business, with strong development in the Emerging Markets, such as Asia, the Middle East, Africa, and Latin America, helping it sustain a double-digit growth rate. The company forecasts 10% growth for ICTx and intends to outperform the rate. The Peripheral Interventions, Interventional Oncology and Embolics businesses collectively represent $11 billion, growing around 7%, with the company aiming to grow above market as well.
Update From Boston Scientific’s Peers
Medtronic (MDT - Free Report) announced that its Diabetes business, soon to operate under the name MiniMed, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected to be completed through a series of capital markets transactions, preferably via an IPO and subsequent split-off. Additionally, Medtronic’s Hugo robotic-assisted surgery (RAS) system has secured FDA approval for use in urologic surgical procedures.
Johnson & Johnson (JNJ - Free Report) has completed the acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. With this acquisition, Johnson & Johnson adds HLD-0915, a clinical-stage therapy for prostate cancer, building on its nearly two decades of innovation in this disease area. In addition, the European Commission has approved the company’s TREMFYA (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor.
BSX Price Performance, Valuation and Estimates
In the past year, BSX shares have climbed 7.5% compared with the industry’s 1.7% rise.
Image Source: Zacks Investment Research
BSX shares are trading at a forward, five-year Price-to-Earnings (P/E) ratio of 27.81, above its median and the industry average.
Image Source: Zacks Investment Research
See how analysts are projecting Boston Scientific’s 2025 and 2026 earnings.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.